Get started
PDS Biotechnology CorporationPDS Biotechnology CorporationPDS Biotechnology Corporation

PDS Biotechnology Corporation

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

PDSB trade ideas

$PDSB Twittering MisinformationStocks are reflections of human interest, and as such they are not paragons of truth. A single strand of misinformation could have catastrophic implications for a stock, which is what happened to PDS Biotechnology Corporation (NASDAQ: PDSB). After an allegation concerning the validity of its trial results was circulated online, the stock sank 51%. That said, the allegation was retracted and social media commentary is reflecting a growing understanding of PDSB stock’s predicament. As is, PDSB stock could be a promising rebound play. PDSB Fundamentals Recently, PDSB released interim data for its phase 2 PDS0101 trial for treating metastatic head and neck cancer. The data showed an 87% overall survivability (OS) rate of 12 months which is extremely promising. Keeping that in mind, the interim data presented also demonstrates that PDSB has developed extremely efficient T Cell technology which raises the bar for its other trials while elevating PDSB stock’s notoriety in the eyes of biotech investors. When PDSB’s integrity was put in question it lost credibility in the eyes of many investors which caused them to sell in mass out of concern that the stock might plummet. After the stock fell 51%, the perpetrator of this slander retracted his comment and deleted the tweet in question. Thankfully, as more light was shed on the issue, biotech investors are likely to regain their interest in PDSB stock. Looking to address these allegations, PDSB is set to execute a conference call on June 6 in which it intends to review and discuss its trial results. This move is likely to reassure investors especially if PDSB provides a meticulously detailed review of its interim data. In light of this, PDSB stock could be one to watch closely as it could rebound to its pre-dip levels soon given its low float of 29.3 million. PDSB Financials According to PDSB’s Q1 2023 report, total assets decreased QoQ from $77 million to $68.4 million. This decline in total assets is mostly attributed to its cash balance which decreased from $73.8 million to $65.1 million. That said, PDSB’s liabilities also decreased markedly from $33 million to $27 million which is mostly due to its current liabilities decreasing from $9.8 million to $4.1 million. PDSB’s total operating expenses increased YoY from $8.4 million to $9.4 million mostly due to PDSB’s many ongoing clinical trials. That said, net loss reflected operating expenses by increasing from $8.4 million to $9.6 million. Technical Analysis PDSB stock was in a bullish trend trading in an upwards channel. That being said, PDSB broke its channel after the sell-off on the false allegations. While the stock may create a new channel, PDSB may retest the lower trendline soon to confirm breaking the channel first. Looking at its indicators, PDSB stock is below the 200, 50, and 21 MAs. However, the RSI is oversold at 28 and the MACD is curling bullishly which might indicate a rebound soon. As for the fundamentals, PDSB recently released very promising Interim results for its PDS0101 phase 2 trial in head and neck cancer treatment. Additionally, more light is being shed on PDSB’s slander, which in turn is promising since it means that the stock could be on the verge of rebounding. Keeping that in mind, the current PPS could be a good entry point in case PDSB rebounds soon as it might result in substantial gains. PDSB Forecast A single slanderous tweet caused PDSB stock to fall 51% in a single day. As a response to the plummeting stock, many biotech investors ventured into Twitter to correct the misinformation circulating online. Additionally, PDSB scheduled a conference call on June 6 to explain its trial results. As more light is shed on the situation, PDSB stock could be a worthy candidate for a rebound play.
NASDAQ:PDSB
by Penny_Stocks_Today
Watchlist 2023-05-30 $MRVL $ON $PDD $PDSB $LXRX $GPSAMEX:SPY is trading sharply higher to start the week post long weekend as a provisional agreement was reached among lawmakers to increase the national debt limit, averting a potential default. This news coincided with an early rally in the market, led primarily by shares of Nvidia, a leading chipmaker and AI firm. SPY had been edging higher each time a new monthly high is made, and continues to fail to make a lower low unless it is faking shorts and sellers out. Key Res for today is 420.50, PD high and pivot high. After that, clear skies up to 430. Key support today is 417, 416, a close near here would signal the start of a multi day reversal. Friday had the characteristics of a positive trend day. If you saw the internals it could have given you the confidence needed to stay in the longs the whole day and possible even add on pullbacks. For further confirmation of a trend day, watch for: USI:ADD pinned near +\-2000 USI:VOLD ratio over +/- 3 USI:TICK cumulating past 0 wicking to +/-900 Chips: Another positive day for chips as NASDAQ:NVDA , NASDAQ:MRVL , NASDAQ:MU all head higher relentlessly. Looking for dips into key levels, and BO's from consolidations where there is at least 2 touches of a level. NASDAQ:PDD - breaking out of a downtrend that everyone and there grandmothers can see. Very strong positive first day after reporting positive earnings so looking for continuation on the trend change, this should be a swing trade as well. First Res at 73 area. Support 71.30 Resistance 80.0 Inflection 73.30 NASDAQ:PDSB - day two continuation long as long as we stay above 8.17 and the tape is bullish (bids are being supported). PDS Biotechnology Shares Rise After Releasing Early Drug Data NASDAQ:LXRX - Lexicon Pharmaceuticals' Cardiovascular, Heart Medication Gets FDA Approval; Shares Rise Premarket. BO from a daily flag on positive drug acceptance news. Up 1.5 ATRs. Has room to at least 3.80 pivot high so if an entry can be placed closer to the 3.30 support that is a great RR trade. NYSE:GPS - Gap stock jumps 12% after surprise profit boost, a loss of .59 a share was expected this quarter but was a profit of 0.01 a share, however, this may be a one time adjustment. Key support, 8.20, and 8.00. This was Friday's run-down. GPS struggled to get past the morning high and couldn't for the entire day. However, now there is a beautiful intraday wedge BO forming. Gap could provide a nice rally if it can get past 8.56. Comment what you are watching!
NASDAQ:PDSB
by UnclePennybagss
Bull flag with high volume on 4H30D chart, w/ potential catalyst~$130mm market cap biotech firm, with multiple products in the pipeline based on their patented Versamune nanoparticle platform. Recently spiked on announcement of award of $60mm from Brazilian Ministry of Science & Technology to fund phase 1/2 clinical trials for a potential Covid vaccine based on their Verasmune platform. Since the news, avg vol (10day) is now 6.5million compared to avg vol (3 month) of 1.7 million. Float of the company is 17.17 million, with approximately $30million cash on hand and a burn rate of ~$5mill per quarter. Hopefully, no immediate offerings. Since initial spike, chart has held steady between $5.50 and $5.00 resistance/support, with it never closing below 5 on the 4 hour candles. On the 24th of March, "Dr. Frank Bedu-Addo, CEO of PDS Biotech, will present the company’s immunotherapy platform, ongoing phase 2 clinical programs, product pipeline and upcoming milestones virtually at the Benzinga Biotech Small Cap Conference" If any interesting information is announced during this conference, it will be interesting to see how the price action follows. Long on this thesis.
NASDAQ:PDSBLong
by adiadv